eIF4B Inhibitors are a class of compounds that target the eukaryotic initiation factor 4B (eIF4B), a critical component of the translation initiation machinery in eukaryotic cells. eIF4B plays a key role in facilitating the recruitment of ribosomes to messenger RNA (mRNA), a process that is essential for the synthesis of proteins. Specifically, eIF4B enhances the helicase activity of eIF4A, another initiation factor, which unwinds secondary structures in the 5' untranslated region (UTR) of mRNA. This unwinding is necessary for the small ribosomal subunit to scan the mRNA and locate the start codon, thereby initiating translation. Inhibitors of eIF4B disrupt this process, potentially leading to a reduction in global protein synthesis, as well as selective effects on the translation of specific mRNAs that are particularly dependent on eIF4B activity.
Research into eIF4B Inhibitors is valuable for understanding the regulation of translation, a fundamental process that controls gene expression at the post-transcriptional level. By inhibiting eIF4B, scientists can investigate the effects on mRNA translation, especially those mRNAs with complex secondary structures in their 5' UTRs, which are more reliant on eIF4B for efficient translation. This can provide insights into how cells control the synthesis of proteins in response to various stimuli and conditions, such as stress, nutrient availability, and signaling pathways. Additionally, eIF4B is known to interact with other components of the translation initiation complex, including eIF3 and the cap-binding protein eIF4E, so its inhibition may shed light on the broader network of interactions that regulate translation initiation. Understanding these interactions is crucial for unraveling the complexities of translational control and its impact on cellular function, growth, and adaptation. Researchers can use eIF4B Inhibitors as tools to dissect these processes, thereby contributing to a deeper knowledge of how cells regulate protein production in both normal and altered states.
VEJA TAMBÉM
Items 11 to 16 of 16 total
Mostrar:
| Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
|---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Os danos no ADN causados pela doxorrubicina podem fazer com que a célula dê prioridade à reparação do ADN em detrimento das funções normais, suprimindo potencialmente a maquinaria de RNAi e diminuindo os níveis de eIF2C2. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
A inibição da topoisomerase I pela camptotecina&prime pode causar danos no ADN, o que pode levar a uma menor concentração nos processos de RNAi e, consequentemente, a uma menor expressão de eIF2C2. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Ao inibir a Hsp90, a Geldanamicina pode desestabilizar as proteínas associadas ao RNAi, o que pode incluir uma diminuição da estabilidade ou síntese do eIF2C2. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Um composto natural isolado da planta Aglaia foveolata, conhecido pela sua potente inibição do EIF4AI. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Outro composto natural encontrado em várias plantas, como as do género Aglaia, com forte atividade inibidora da EIF4AI. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $193.00 $813.00 | ||
Um inibidor sintético de EIF4AI concebido para perturbar o complexo eIF4F, inibindo assim a tradução dependente de cap. | ||||||